Celltrion Completes Resubmission to FDA for Proposed Trastuzumab Biosimilar | Business Wire
Celltrion clinches 110 bln-won drug substance supply deal from Teva | Yonhap News Agency
Teva: 'Celltrion deal will double biosimilar sales to $600m'
Celltrion's manufacturing headache likely to delay Teva migraine drug until 2019: analysts | Fierce Pharma
Celltrion partners with Canada's iProgen Biotech
Teva: 'Celltrion deal will double biosimilar sales to $600m'
Partners Teva/Celltrion Seek the Jump on Pfizer, Launch Their Rituximab Biosimilar Next Week
Teva and Celltrion Announce Exclusive Biosimilar Commercial Partnership - Drug Discovery and Development
Teva and Celltrion Launch Trastuzumab Biosimilar in U.S. - Big Molecule Watch
Celltrion and Teva Snag Second Biosimilar Approval of a Genentech Drug | BioSpace
Celltrion clinches W110b drug substance supply deal from Teva
Genentech Settles Rituximab Patent Dispute with Celltrion and Teva - Big Molecule Watch
Teva teams up on biosims with Celltrion three years after its Lonza JV divorce | Fierce Biotech
Teva, Celltrion launch Herceptin biosimilar in US - Globes
Celltrion stuns the market with merger and expansion plan for this year - Pulse by Maeil Business News Korea
Celltrion FDA warning causes headache for Teva's biologics ambition
Teva and Celltrion Announce the Availability of TRUXIMA® (rituximab-abbs) Injection, the First Biosimilar to Rituxan® (rituximab) in the United States | Business Wire
Teva bolsters its biosimilar business through $160m Celltrion deal
Teva two: FDA approves Celltrion-made Herceptin biosimilar - BioProcess InternationalBioProcess International
Teva, Celltrion Launch Fourth Trastuzumab Biosimilar
Celltrion signs $160m drug license deal with Teva for North America - Nikkei Asia
Teva, Celltrion Gain FDA Approval for Generic Blood Cancer Bio-Drug | Ctech
Teva and Celltrion Announce the Launch in the U.S. of Biosimilar to Rituximab for Rheumatoid Arthritis | TechnoPharma | Дзен
